Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Procare Health: Silencing HPV infection may exacerbate the physiological effects…

The session also discussed proactive strategies for HPV management, including the use of Papilocare® products. Clinical trials involving over 600 patients demonstrated Papilocare® vaginal gel's efficacy in normalizing cervical lesions and clearing high-risk HPV strains. Notable studies as the Paloma clinical trial, published in the American scientific journal Journal of Lower Genital Tract Diseases, or the observational study Papilobs, published last July in the prestigious journal Cancers…

MGI Tech and Eurofins Genomics Partner to Elevate Precision Health with…

Powered by MGI's proprietary DNBSEQTM technology, T20 represents a breakthrough in genetic sequencing by significantly reducing sequencing costs to below $100 per genome when running 50,000 WGS per year, garnering global attention. Specifically designed to address the most challenging sequencing scenarios, T20 caters to a wide array of high-throughput sequencing needs in scientific and clinical research, including WGS, WGBS, stLFR, single-cell sequencing, Stereo-seq, and more. Following its…

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; March 4, 2024 – Genmab A/S (Nasdaq: GMAB).On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares.The following transactions were executed under the program from February 26 to March 1, 2024: No. of sharesAverage price...

Affidea enters into an agreement to acquire MedEuropa Romania

Razvan Predica, Country CEO for Affidea Romania and Hungary, stated: "Cancer is claiming far too many lives in our communities, with approximately 100,000 people being diagnosed with an oncological disease in Romania every year. This acquisition isn't just about growth; it's about standing shoulder-to-shoulder with the National Health System and those affected by this relentless disease. We look forward to working with the great team of MedEuropa following the closing and continue…

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent…

This study was led by Professor Jihong Liu from the Sun Yat-sen University Cancer Center and Professor Hanmei Lou from the Zhejiang Cancer Hospital. This was a multi-center, single-arm, phase II study which recruited patients with recurrent or metastatic cervical cancer unresponsive to first-line platinum-based chemotherapy (with or without bevacizumab) and without prior immunotherapy. Participants received QL1706 at a dose of 5.0 mg/kg once every three weeks (Q3W). The study involved 38 medical…

Insightec's Groundbreaking Transcranial MR-Guided Focused Ultrasound (MRgFUS)…

The Germany Institute for Hospital Remuneration's decision to award NUB status 1 aligns with the Federal Joint Committee's (G-BA) recognition of MRgFUS therapy for ET treatment in 2021[1]. Effective immediately, approved hospitals can negotiate add-on payment within the German national reimbursement system, showcasing the country's commitment to providing innovative solutions. The Germany Institute for Hospital Remuneration's decision to award NUB status 1 aligns with the Federal Joint...

Sectra's enterprise imaging solution now covers majority of US patients in the…

For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27 Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10 For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10 The following...

Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)

Vistin Pharma has aquired a 15% share in CF Pharma Kft. CF Pharma is an API CDMO located in Budapest, Hungary with a broad customer base of recognized international pharmaceutical companies. CF Pharma has a proven track record in developing and commercializing Active Pharmaceutical Ingredients (APIs). The group/company currently has five commercial APIs on the market, with another eight APIs under development.The transaction price consists of a base price and an earn-out- element, with an...

Novartis presents new data on safety and efficacy of Zolgensma, including…

The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies 1-6 Nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy 1-6The SMART study is the first open-label clinical study of Zolgensma to include...

Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of…

Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer ' s DiseaseVIVIAD Phase 2b study did not meet its primary and key secondary endpointsVaroglutamstat was generally well tolerated with low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs in the clinical settingVIVIAD is a comprehensive, diligently designed and high-quality study; baseline demographics in the study were highly...

KSrelief: Successful surgical separation is just the beginning for Nigerian…

"Following a lengthy recovery process, the twins will be blessed with the promise of a normal life full of hope and opportunity," said Dr. Al Rabeeah. "We are so happy to have had the opportunity to help Hassana and Hussaina. We will continue to monitor the twins and will do everything we can to ensure steady progress and recovery in the weeks ahead." "Following a lengthy recovery process, the twins will be blessed with the promise of a normal life full of hope and…

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare…

Saint-Herblain (France), March 4, 2024 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach will present Valneva at the TD Cowen 44th Annual Health Care Conference, taking place March 4 - 6, 2024, in Boston, MA. Mr. Lingelbach and CFO Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen...

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and…

MEDIA RELEASE CIMERLI ® *, a ranibizumab biosimilar, is interchangeable with LUCENTIS ® ** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patientsBasel, March 4, 2024 –Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI ® * (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of...

Ultimovacs announces publication of results from NIPU Phase II trial with UV1…

NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of pleural mesothelioma. The results were initially presented at the ESMO Conference in October 2023The publication outlines the full trial results, including observations on UV1's positive impact on objective response rate, overall survival, and additional data on increased efficacy in defined histological subtypesOslo, March 2, 2024:Ultimovacs ASA...

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; March 02, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish...

The 16th Zhang Zhongjing Medicine Culture Festival & Forum on High-quality…

In addition to live streaming and interactive online sessions that engaged over 2 million virtual participants, the forum facilitated concurrent trade negotiations and a project-signing event that culminated in the execution of agreements for 58 projects, with a combined investment totaling 36.4 billion yuan. The Zhongjing Comprehensive Health Care Industry Expo, an integral part of the forum, featured nine exhibition areas with 180 booths, hosting over 200 Chinese TCM companies and attracting…

Orion Corporation: Managers' transactions – Olli Huotari

Orion Corporation: Managers' transactions – Juhani Kankaanpää

Orion Corporation: Managers' transactions – Hao Pan

Orion Corporation: Managers' transactions – Liisa Hurme

Orion Corporation: Managers' transactions – Outi Vaarala

Orion Corporation: Managers' transactions – Virve Laitinen

Orion Corporation: Managers' transactions – Satu Ahomäki

Hybribio Calls for Raising International HPV Awareness

Procare Health: Silencing HPV infection may exacerbate the physiological effects…

MGI Tech and Eurofins Genomics Partner to Elevate Precision Health with…

Transactions in connection with share buy-back program

Affidea enters into an agreement to acquire MedEuropa Romania

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent…

Insightec's Groundbreaking Transcranial MR-Guided Focused Ultrasound (MRgFUS)…

Sectra's enterprise imaging solution now covers majority of US patients in the…

Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)

Novartis presents new data on safety and efficacy of Zolgensma, including…

Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of…

KSrelief: Successful surgical separation is just the beginning for Nigerian…

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare…

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and…

Ultimovacs announces publication of results from NIPU Phase II trial with UV1…

Transactions with shares and linked securities in Genmab A/S made by managerial…

The 16th Zhang Zhongjing Medicine Culture Festival & Forum on High-quality…